Navigation Links
DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
Date:9/9/2013

ffer from other alkylating agents used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies.  Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as O6-methylguanine methyltransferase (MGMT), may not confer resistance to VAL-083.  

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life compared to plasma.  Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as a chemotherapy in the treatment of newly diagnosed and recurrent brain tumors.  In general, tumor regression was achieved following therapy in greater than 40 percent of patients treated and stabilization was achieved in an additional 20 to 30 percent.  In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high-grade gliomas when combined with radiation versus radiation alone. 

The main dose-limiting toxicity related to the administration of VAL-083 in previous clinical studies was myelosuppression.  No significant hepatic, renal or pulmonary toxicity has been reported. 

About Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. and Zhongheng Group Co. Ltd.

Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., a wholly owned subsidiary of Zhongheng Group Co., Ltd. (SHG   600252) is principally engaged in the manufacture of pharmaceuticals.  The Company's main products include cardiovascular drugs, medicine for bruises, and gynecology medication, among others.  Zhongheng Group is also involved in the investment and management o
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
2. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
4. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
5. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
7. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
10. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
11. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report ... Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), ... MarketsandMarkets, the Medical Lifting Sling Market is poised to reach USD ... a CAGR of 11.4 % from 2015 to 2020. ... data T ables and 65 F ...
(Date:8/27/2015)... , Aug. 27, 2015   Proxsys ... Provider (IOPP™) is expanding its population health ... medication-focused transition of care program for hospitals ... Management," provides hospitals with technology systems and ... measures that have been mandated by Center ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... Ontario, Dec. 12, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... the Federal Trade Commission (FTC) voted unanimously to approve the ... dermatology unit of Sanofi (EURONEXT: SAN and NYSE: ... division of Janssen Pharmaceuticals, Inc. As a ...
... PharMEDium announced the first generation solution ... Operating Room (O.R.).  PharMEDium has developed the ... "Our certiMED™ system is designed to be ... Ready-to-Use O.R. syringe medications by providing a visual and ...
Cached Medicine Technology:Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik 2PharMEDium Adds O.R. Medication Verification System 2
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and ... to its cadre of widespread support—an official letter of support and gratitude from the ... community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... West Jordan, Utah (PRWEB) , ... August 28, ... ... has been awarded a three-year accreditation for its adolescent residential, counseling, day treatment ... Academy demonstrates that it meets international standards for quality and its pursuit of ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... use of incense increases the risk of developing cancers of ... analysis, which the authors say is the first prospective investigation ... 2008 issue of CANCER, a peer-reviewed journal of ... of daily life in large parts of Asia. Researchers have ...
... Mich., Aug. 22 Stryker Corporation,(NYSE: SYK ) ... conferences:, September 3, 2008 - 9:45 a.m. ... Boston, Massachusetts, September 17, 2008 - 9:30 ... 2008 London, England, Simultaneous webcasts of the ...
... reduce unhealthy behaviors like binge drinking and eating junk ... But a new study in the Journal of Consumer ... to improve consumer health. , Authors Jonah Berger ... that linking a risky behavior with an "outgroup" (a ...
... hotel towels if they know other guests are doing ... Journal of Consumer Research examined participation rates in ... Authors Noah J. Goldstein (University of Chicago), Robert B. ... that the types of signs posted in hotel bathrooms ...
... Technology approved for control of food-borne pathogens in ... Robert Brackett, chief,science officer for the Grocery ... response to the U.S. Food & Drug,Administration (FDA) ... for,controlling food-borne pathogens in fresh iceberg lettuce and ...
... use eRx Network Medicare Part B transaction ... processing services in its stores nationwide, FORT WORTH, Texas, ... transaction services to the retail pharmacy,industry, announced today that it ... Part B claims, state,Medicaid DME claims and clinical administration programs ...
Cached Medicine News:Health News:Burning incense increases risk of respiratory tract cancers 2Health News:Stryker to Present at Investor Conferences 2Health News:Part of the in-group? A surprising new strategy helps reduce unhealthy behaviors 2Health News:A room with a viewpoint: conservation messages and motivation 2Health News:Grocery Manufacturers Association Strongly Supports U.S. Food & Drug Administration Decision on the Irradiation of Fresh Produce for Foodborne Pathogen Control 2Health News:eRx Network to Provide Transaction Processing and Revenue Cycle Management Services to Rite Aid 2
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
Beta-2 Microglobulin EIA Lipid / Protein Quantification 025-BC-1061...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Human Growth Hormone EIA Endocrine Function 025-BC-1033...
Medicine Products: